1. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
- Author
-
Zhang, Xu-chao, Cao, Xu, Sun, Chun, Xie, Zhi, Guo, Jian-jun, Yang, Jin-ji, Yang, Xue-ning, Dai, Hang-jun, Li, Su-chun, Xu, Xin-ran, Zuo, Yun-xia, Chen, Meng, Koeppen, Hartmut, He, Jing, Kiermaier, Astrid, Shames, David, Cheng, Gang, and Wu, Yi-long
- Subjects
- *
NON-small-cell lung carcinoma , *PHOSPHATASES , *PUBLIC health , *MICROARRAY technology , *HEALTH outcome assessment , *PROGRESSION-free survival , *PATIENTS - Abstract
The goal of this study is to evaluate PD-L1 prevalence and its association with major clinical characteristics in Chinese non-small cell lung cancer (NSCLC) patients to inform the clinical development of anti-PD1/PD-L1 agents in this population. We used phosphatase and tensin homolog (PTEN) expression through IHC as a surrogate tissue quality marker to screen surgical NSCLC samples in tissue microarray (TMA; 172 cases) or whole-section (268 cases) format. The samples were then analyzed with a clinically validated PD-L1 IHC assay. The results were correlated with baseline characteristics and clinical outcomes. PTEN IHC showed that 108 TMA samples and 105 whole-section samples qualified for PD-L1 IHC. With a clinically relevant cutoff, 41.7% of the TMA samples were PD-L1 positive. PD-L1 level was much lower in EGFR-mutant patients and seemed to be a favorable prognostic factor for both overall survival (OS) and recurrence-free survival (RFS). These findings were confirmed in the whole-section samples except that their survival data were not mature enough for correlation analysis. In summary, PD-L1 expression was detected in approximately 40% of PTEN-qualified Chinese NSCLC samples, negatively correlated with EGFR mutation and seemed to be a favorable prognostic factor for both OS and RFS. Notably, the different results from PTEN-qualified and PTEN-disqualified samples underscore the importance of tissue quality control prior to biomarker testing. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF